Prior to Epirium, she was an investor on the Biotech Team at Longitude Capital. Daniels primary responsibilities include creating competitive landscapes of climate change solutions and analyzing investment opportunities across climate technology and applied biotech. Drinking, Drugs & Smoking Not present. Patrick received his PhD in Natural Sciences, specifically Biochemistry and Molecular Biology, from the Leopold-Franzens University, Innsbruck, Austria. He earned an MS in chemical engineering and his MBA and PhD in engineering systems from MIT. He holds a BA in Environmental Engineering from Dartmouth College (1998), an MA in International Finance and Energy Policy from John Hopkins University (2008), an MS in Materials Science from Columbia University (2012), and a Masters of Strategic Studies from the Army War College (2020). Tom Thomas is an Associate with the TechAtlas division of RA Capital Management. In 2013 was awarded a Medical Research Council Clinical Scientist Fellowship. The Great American Drug Deal examines the healthcare landscape through the lens of this contract, including the government's role in inventing drugs, direct-to-consumer advertising, the opioid crisis, the price-jacking of old drugs, and the impact on America of lower drug costs in other countries. In this episode Peter speaks with Dr. Wayne Shreffler, Director of the Food Allergy Center at Massachusetts General Hospital & Division Chief of Pediatric Allergy and Immunology at MassGeneral Hospital for Children. He was a faculty member at the University of Rochester School of Medicine prior to joining Merck Research Laboratories in 2004. Prior to Indigo, Kathryn was Investment Principal at the Massachusetts Clean Energy Center (MassCEC) where she invested in enterprise and consumer-facing clean energy companies, including software and hardware companies focused on utility and grid resilience, grid edge, next-generation renewables, efficient mobility, industrial efficiency, sustainable buildings, and the water-energy nexus. Patrick joined TRIANA Biomedicines in December of 2021 as President & CEO and Board member after a successful career at Constellation Pharmaceuticals where he served as the companys CSO. Parents Need to Know. He co-founded and runs the Boston-based investment firm RA Capital Management; writes and teaches about biomedical entrepreneurship and its potential to transform global health; serves on the boards of several public and private drug development companies; and lives in Massachusetts with his historian/equestrian wife, strong-willed children, and reasonably well-trained dog. From 2016-2017, Scott served as President of Sojournix, Inc., an asset-focused biopharmaceutical company that he co-founded and served as Board member until 2021. Shan Shan Wang is an Associate Director within the TechAtlas division at RA Capital Management. Adisons primary responsibilities are to coordinate calendars, events, and company meetings for the Investment Team. She holds a BA in Public Administration with a minor in International Affairs from Texas State University. PETER KOLCHINSKY, PhD Managing Partner RAJEEV SHAH Managing Partner ANDREW LEVIN, MD/PhD Partner and Managing Director JOSH RESNICK, MD Senior Managing Director PETER BALOGH Analyst GUNES BOZKURT, PhD Analyst TESS CAMERON Principal NATE DAVIS Analyst DEREK DiROCCO, PhD Partner CRISTINA GHENOIU, PhD Principal MICHAEL GILLESPIE, MD Analyst Jess'sprimary responsibility is to direct a concerted effort to analyze, design, and shape internal and external narratives. Alex has a BA with a triple-major in Finance, Economics, and Math from UMass Lowell. Most recently, Tom served as Director of Operations at TPRV Capital, LP. He received his doctorate in Organic Chemistry from Ohio University, and was a Fellow and Instructor in Department of Medicine, Boston University School of Medicine. Most recently, she was as an Entrepreneur-in-Residence at RA Ventures and was a Scientific Co-Founder and Associate Director of Corporate Development at Athenen Therapeutics (merged into Eliem Therapeutics; ELYM). Previously, Nate covered atopic dermatitis, psoriasis, dermatology, colorectal cancer, cancer diagnostics, and broader tools and diagnostics as a Senior Associate within RAs TechAtlas division. Erins primary responsibilities at RA Capital are to manage the design and creation of all internal and external documents and resources for the company, including competitive landscapes of drugs and medical devices for disease indications and capabilities, set brand standards, and oversee internal and external marketing efforts. Jaimie previously held roles in non-profit and medical settings and worked at Goldman Sachs where she was an Executive Assistant. Peter Kolchinsky 285 Followers Scientist turned biotech investor, always learning, guided by fatherhood, share The Economist's world view, inspired to write by Hamilton's Federalist Papers. GREENWICH Peter Crumbine, a mainstay of public service in Greenwich for decades whose level-headed, friendly and professional manner earned . Alex has a BS in Chemistry and a Minor in Religious Studies from Davidson College. Not so long ago, his mother and father were not rich. Brendans primary responsibility is managing all aspects of the tax function. While at Johns Hopkins, she spent two years as a Research Intern and Teaching Assistant in the Department of Biology and the Department of Chemistry. Barrie's 1911 novel. in Biomedical Anthropology from the University of Pennsylvania. Peter Kolchinsky, Founder and Managing Director of RA Capital Management, L.P. and Founder of the nonprofit No Patient Left Behind, sits down with Liked by Peter Kolchinsky We need YOU to help. Laura Stoppel is a Principal on the Investment Team at RA Capital Management. She is a CPA. Katherines primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Tim was hired as the fourth employee at Proteon and built a team that brought an innovative biologic for blood vessel remodeling from pre-clinical through two Phase 3 clinical trials. Joey holds a Bachelor of Science in Finance from American University and is FINRA-certified in Series 7, Series 63 and Securities Industry Essentials. Peter Kolchinsky is a founder and Managing Partner at RA Capital Management and author of The Great American Drug Deal. Angela's primary responsibilities at RAVen are to lead development and oversee implementation of best practices in clinical strategies in RA's newcos and portfolio companies. in Business Administration in Management Information Systems from Northeastern University. Prior to his career at the Broad Institute, Robert was an MIT Leaders for Manufacturing Fellow, and a project manager for Fluor Corporation, where he managed large-scale petrochemical design and construction projects. Previously in his career, he served as Associate General Counsel at Millennium Pharmaceuticals (now Takeda Oncology) where he built the legal department and led internal legal activities supporting several transformative pharmaceutical partnerships, a substantial global patent estate, and the companys IPO. Prior to joining RAVen, Maryann was Director of Business Operations and HR at Q32 Bio where she wore many hats helping to establish the companys business infrastructure including IT, contract management, facilities, administrative support, Human Resources, recruiting, internal communications and was a strong driver of company culture. Prior to RA, Laura was a Principal at MP Healthcare Venture Management. Benjamin Hicks is a Venture Operations Associate at RA Capital Management. Gerald is Vice President of Scientific Operations at RA Ventures (RAVen). He completed the Executive Program at Stanford University, Graduate School of Business, as well as the Executive to Leader Institute at Korn/Ferry International. Ramaswamy, who just turned 30, has bigger aspirations. Ramin is an experienced clinical trialist and previously led global clinical development programs at Akebia Therapeutics and Gilead Sciences. In these commercial roles, he initiated innovative discovery deal structures with venture companies, research foundations, and large integrated deals with pharmaceutical companies. Matt Beverly is a Senior Software Engineer at RA Capital Management. Under his leadership, Therapeutics Alliances advanced 40+ projects, including 11 projects partnered with biopharma or new startups such as Repare Therapeutics and GliXogen Therapeutics. Prior to GHP, Lorena served as an Assurance Senior at EY. Jessica manages RA's Innovator Resources and co-founded RApport, our biotech communications platform. Prior to RA, Ryan was at KPMG where he was a Senior Associate. Kate Moreau is an Associate Director within the TechAtlas division of RA Capital Management. Natalie Camacho is an Executive Assistant at RA Ventures (RAVen). Erich holds a BA in English Literature and Language from Harvard University and a PhD in Microbiology from the University of North Carolina, Chapel Hill. Adam has led and advised companies in diverse areas such as digital health, materials and diagnostics, and has served as Director on the board of multiple venture-backed companies. Phi's primary responsibilities at RA Capital are to support the Operations team by coordinating calendars, events, and company meetings. He co-founded and runs the Boston-based investment firm RA Capital Management; writes and teaches about biomedical entrepreneurship and its potential to transform global health; serves on the boards of several public and private drug development companies; and lives in Massachusetts with his historian/equestrian wife, strong-willed children, and Dan Guglielmo is IT Operations Associate at RA Capital Management. Kathryn Meng is an Investment Director within the Planetary Health division of RA Capital. Our website uses cookies to distinguish you from other users of our website. Robert has led multiple DARPA, IARPA, and NIH advanced technology development programs. TJ is a Senior Fund Accountant at RA Capital Management. Michael Gillespie is an Analyst on the Venture Team at RA Capital Management. Peter Kolchinsky was born in the United States of America. Brett Scheller is a Compliance Officer at RA Capital Management. She received a BA from Princeton University and an MBA from Harvard Business School. Kriti Subramanyam is an Associate within the TechAtlas division of RA Capital Management. Her graduate research investigated novel epigenetic regulators in glioblastoma. Candice previously worked as the Director of Executive Office and Administration at Flywire. Matts primary responsibility at RA Capital is to help guide internal software development to support competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Harveys primary responsibility is to oversee all accounting related activities for the firm. Cameron has a BA in Neurobiology from Harvard University. He holds a MS from Northeastern University and a BA from Hamilton College. Any hedge fund managing over $100M is required to submit a 13F form to the SEC which lists their current holdings at the end of each fiscal quarter. She has spent the last five years as a Senior Finance Associate at Great Hill Partners. Early in his career, Mr. Grau worked with multi-national pharma companies including Pharmacia, Pharmacia & Upjohn, and Eisai as a management consultant focused on corporate strategy, M&A, and new product launch. He has over 20 academic publications, inventorship on numerous patents, and serves as reviewer for multiple journals and NIH grants committee. Prior to Citigroup, he held various accounting and analyst roles at EY, Morgan Stanley, BBH, and Deloitte. James Schneider is the Deputy General Counsel at RA Capital Management. Prior to joining RA Capital, Emilie was a Vice President of Investor Relations at THL Credit. Most recently, Joe led the administration and support of all Apple products at Curriculum Associates as an IT Systems Engineer. Laura works on new company creation and early-stage investments, and serves as a Board Director for Be Biopharma, Expansion Therapeutics, Hemab, and Aliada Therapeutics. Walter has a BS in Biology from Davidson College and a MS in Genetics from University of Georgia. He holds a BS in Computer Engineering and a Minor in Mathematics from Northeastern University. Sarah is the only lawyer to have received the NVCAs Outstanding Service Award, for her leadership role in conceiving of and spearheading the NVCA Model Legal Documents. Brian has a B.S. Prior to BEV, Kyle was a Principal at In-Q-Tel, the strategic investment arm of the CIA and US Intelligence Community, where he invested in early stage manufacturing, materials, energy, computing, and defense companies. All information is subject to change and may quickly become unreliable for various reasons, including changes in market conditions or economic circumstances. She previously served as Senior Vice President, R&D Operations & New Product Planning at Epirium Bio. Mario held a Project Director position at BARDA working on Universal Flu Vaccine and leading the technical selection and completion of multiyear/multi million vaccine development programs. Le Ho is a Business Systems Analyst at RA Capital Management. Finally, they made it to the Boston. Henry Stusnick is an Associate at RA Capital Management. Candice has a BS in Mass Communications from Emerson College. Asia Pacific +65 6212 1000. Roivant, he . Prior to RA, Kevin was a postdoctoral associate at the Broad Institute of MIT and Harvard and an EMBO fellow. Merediths previous experience includes Medical Education Researcher and Medical Scribe positions at BMC Global Inc. and Longwood Pediatrics, respectively. Milind attended the residential Executive Program at The Wharton School of Management. She has a BA in Communication Studies from University of Minnesota, Twin Cities. Tess works on both public and private investments and serves on several company boards. All rights reserved. Previously, Daniel spent time working at ARPA-E and the Center for Climate and Energy Solutions, and has published research examining potential early markets for fusion energy as well as techno-economic synergies between direct air capture and advanced nuclear. Christina is a Senior Science Writer at RA Capital Management. Kat Riesen is the VP, Finance at RA Ventures (RAVen). His primary responsibilities are to advise RA Capital on private investments, coordinate with portfolio companies regarding deal structures and terms, and counsel RA Ventures on new company formation. Michael Varnum is a Research Assistant at RA Capital Management. Brian previously worked at the Kraft Group LLC, where he led their system admin, network, and desktop engineering groups. Tweet With huge thanks to RA Capital's Alex Martinez-Forte and Jacqueline Rhuda for extensive data analysis. He is a member of the Advisory Boards of the Applied Biotechnology Laboratory at the Francis Crick Institute, the Center for Surgery,Innovation & Bioengineering at the Massachusetts General Hospital/Harvard MedicalSchool; the Chemical& Biomolecular Engineering Department of the University of Illinois and the Biomedical Engineering Departmentof Rutgers University. Craig holds a BA in Political Science from Bridgewater State College and a JD from Boston College Law School. His prior posts include Fund Accountant at Nautic Partners and HLM Venture Partners. Gabe Fox is an Associate with the TechAtlas division of RA Capital Management. Becca has a BA in Biology from Colgate University and a PhD in Biology from MIT. During his time at Flagship, Tom also served as Co-Founder, Head of Translational Biology at a stealth ProtoCo. Alex is an Associate with the TechAtlas division of RA Capital Management. Alonso completed his Ph.D. in Chemistry at the University of Florida and his post-doctoral work as a Howard Hughes Medical Institute Fellow at Harvard University and the Massachusetts General Hospital. Peter Kolchinsky is a founder and Managing Partner at RA Capital Management and author of The Great American Drug Deal. He holds a BA from Cornell University and a PhD in Virology from Harvard University. He holds a BS in Computer Science from The University of California, San Diego, and worked previously as a Software Engineer at IBM and Fidelity Investments. Join Peter Kolchinsky on his first episode of Future in Sight, a new podcast from FARE. Merediths primary responsibility is to conduct research and analysis for competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Previously, Michael worked closely with the Investment Team, to originate conviction in potential investments by identifying breakthroughs and putting data into context, as well as advising RA's portfolio companies on many aspects of program and pipeline strategy. Vanderpump Rules' Peter Madrigal's Age. Derek holds a BA in Biology from Holy Cross College and a PhD in Pharmacology from the University of Washington. Mark began his professional career as a life sciences attorney with the law firm of Hale and Dorr (now WilmerHale). He has served on the Board of Directors of Sojournix, Inc., AltusPharmaceuticals (Nasdaq: ALTU) and the CellScape Corporation. Jon Lundt is a Senior Associate within the TechAtlas division of RA Capital Management. In that role, Joel led teams responsible for advancing more than 40 compounds into clinical development, including Sprycel (dasatinib), which he co-invented. Before joining Rubius, Mark spent a decade launching, building or advising a portfolio of early-stage venture backed life-sciences companies, including Visterra, Living proof, Kala Pharmaceuticals, and Homology Medicines. Jessica Sagers is Head of Engagement at RA Capital Management. Sonia Kartha is an Associate with the TechAtlas division of RA Capital Management. Sris primary responsibility at RA Capital is to help guide internal software development to support competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Mr. Grau earned his BA with High Honors from Davidson College, where he was awarded a Dana Honor Scholarship and elected to Phi Beta Kappa, and his MPhil, MA, and MAR degrees from Yale University, where he was awarded the Day Graduate Prize and was the recipient of a Mellon Fellowship in the Humanities. Josh holds a BS in Genetics, Genomics, and Biotechnology with a Minor in Business from Brigham Young University. Kathryns primary responsibility at RA is to invest in companies developing solutions that address climate change and environmental sustainability. Asthas previous experience includes Research Assistant roles at Clark University and Corbus Pharma. His doctoral research focused on breast cancer metastasis. He was Vice President of Merck business development and licensing where he led BD activities in the US (West Coast), Europe, and Asia Pacific region, as well as President of MRL Ventures where he led equity investing in early-stage therapeutics companies. Dan holds a BS with Honors in Biology from Yale University and a PhD in Cancer Biology from the Gerstner Sloan Kettering School of Biomedical Sciences. Erin Clutter is the Head of Graphics at RA Capital Management. Jesse Chen is an EIR at RA Capital. His graduate research investigated innate immune responses after intracerebral hemorrhage. Cosmas received his BS in Physics from Massachusetts Institute of Technology and his MD from Rutgers-New Jersey Medical School. Erin holds a Bachelor of Fine Arts degree from the Massachusetts College of Art & Design. Prior to joining the team at Enara Sophie was a medical oncologist at Guys and St Thomas NHS Foundation Trust in London, UK (GSTT). He conducted his postdoctoral research at Brigham and Womens Hospital/Harvard Medical School, where he researched the role of the Wnt signaling pathway in mouse models of kidney disease, and was part of a team that discovered a stem cell subtype responsible for solid organ fibrosis. Peyman Hosseinchi is an Associate within the TechAtlas division of RA Capital Management. Senior executives interested in a position with one of our portfolio companies are also welcome to submit their resume and a description of their desired position. Michael Ryan is an EIR at RA Capital. Daniels primary responsibility at RA Capital is to edit and guide development of competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Derek DiRocco is a Partner at RA Capital Management. Prior to MPM, Sarah was the General Counsel for Charles River Ventures and before that, at Palomar Medical Technologies. Josh is currently a faculty member at Harvard Medical School and continues to practice medicine as an attending physician in the Department of Emergency Medicine at Massachusetts General Hospital. Abhishek is a Data Analyst Associate at RA Capital Management. Dans primary responsibility at RA Capital is to provide technical assistance and support for issues related to computer systems, the network, and server environments. Sophie received her doctorate in CAR T cell therapy from Kings College London, her pre-clinical medical degree from St Johns College, University of Oxford, and her clinical medical degree from Imperial College London, where she won the Norman C Lake prize for Surgery. Nate Davis is an Analyst on the Investment Team at RA Capital Management. Elena's primary responsibility at RA Capital is to create competitive landscapes of biotechnology and planetary health. Laura previously worked at WinterWyman where she served as a Senior Associate. 1 reply 0 retweets 13 likes Sri Mahendra is a Senior Software Engineer at RA Capital Management. Ed began his career working with neurologically active compounds at Allergan, CoCensys, and Serono. Erichs primary responsibilities are to drive internal and external strategic and diligence initiatives and oversee the workflow and professional development of TechAtlas Associates. Prior to MassTech, Natalie held varying Administrative roles at Northeastern University, Framingham Public Schools, and Bright Horizons Family Solutions. Joe DeMaio is IT Operations Associate at RA Capital Management. Peter Kolchinsky, Ph.D. Jeff holds a BA in Economics and Psychology from Georgetown. Kathryn has a BS in Exercise and Health Science from the University of Massachusetts Boston. Prior to MPM, she worked as an Executive Assistant at Charles River Ventures. Before her time at New Care, she was a Student Researcher at Boston Childrens Hospital Labs of Cognitive Neuroscience. Her primary responsibilities are to coordinate calendars, events, travel and meetings for the Venture Partners and Entrepreneurs-In-Residence within RAVen.